This map shows the geographic impact of Bill McBride's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bill McBride with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bill McBride more than expected).
This network shows the impact of papers produced by Bill McBride. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bill McBride. The network helps show where Bill McBride may publish in the future.
Co-authorship network of co-authors of Bill McBride
This figure shows the co-authorship network connecting the top 25 collaborators of Bill McBride.
A scholar is included among the top collaborators of Bill McBride based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Bill McBride. Bill McBride is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Karacay, Habibe, et al.. (2010). A new tri-Fab recombinant bispecific antibody (bsMAb) for pretargeting epithelial cancers: Studies with TF12 and 111In-labeled hapten-peptide (IMP 288) in ovarian cancer. 51. 1148–1148.3 indexed citations
2.
Schaijk, Frank G. van, Egbert Oosterwijk, Janneke D.M. Molkenboer‐Kuenen, et al.. (2005). Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.. PubMed. 46(3). 495–501.40 indexed citations
3.
Schaijk, Frank G. van, Egbert Oosterwijk, Bill McBride, et al.. (2005). Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.. PubMed. 46(6). 1016–22.19 indexed citations
4.
Stein, Rhona, Serengulam V. Govindan, M. Jules Mattes, et al.. (2003). Improved iodine radiolabels for monoclonal antibody therapy.. PubMed. 63(1). 111–8.59 indexed citations
5.
Maggiore, C.J., S. Möller, Jørgen B. B. Petersen, et al.. (2002). Relative Biological Effectiveness and Peripheral Damage of Antiproton Annihilation. CERN Bulletin.1 indexed citations
Boerman, O.C., et al.. (1998). Two-step targeting of RCC tumors in mice : Improved tumor uptake and retention with a bivalent chelate. University of Groningen research database (University of Groningen / Centre for Information Technology). 39(5).5 indexed citations
8.
Lister‐James, John, Shankar Vallabhajosula, Brian R. Moyer, et al.. (1997). Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide.. PubMed. 38(1). 105–11.20 indexed citations
Taylor, Stephan F., Kirk A. Frey, Ronald M. Baldwin, et al.. (1992). Technetium-99m-N1-(2-mercapto-2-methylpropyl)-N2-(2-propargylthio-2- methylpropyl)-1,2-benzenediamine (T691): preclinical studies of a potential new tracer of regional cerebral perfusion.. PubMed. 33(10). 1836–42.7 indexed citations
McBride, Bill, et al.. (1977). The proceedings of the EURES Symposium on the macrophage and cancer : proceedings of the European Reticuloendothelial Society Symposium, held in Edinburgh, September 12-14th, 1977. Medical Entomology and Zoology.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.